Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients.

Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Abstract Text:

    masayuki kurosakiMasayuki Kurosaki,namiki izumiNamiki Izumi,yuko onukiYuko Onuki,yuki nishimuraYuki Nishimura,ken uedaKen Ueda,kaoru tsuchiyaKaoru Tsuchiya,hiroyuki nakanishiHiroyuki Nakanishi,takatoshi kitamuraTakatoshi Kitamura,yasuhiro asahinaYasuhiro Asahina,masakatsu uchiharaMasakatsu Uchihara,shozo miyakeShozo Miyake,

    The up-regulation of MUC1 protein is associated with malignant phenotype of cancer. We investigated the significance of KL-6, one of the MUC1 antigens, as a tumor marker in hepatitis C virus positive hepatocellular carcinoma (HCC). Serum KL-6 was determined in 203 patients with chronic hepatitis (CH), 47 patients with liver cirrhosis (LC) and 78 patients with HCC. KL-6 was higher in HCC compared to non-HCC (p=0.0005) and was higher in patients with multiple HCC nodules compared to a single nodule (p=0.02). There was no correlation between KL-6 and existent tumor markers for HCC such as alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein or des-gamma-carboxyprothrombin. In the prospective analysis, the cumulative incidence of HCC was significantly greater in CH and LC patients with high initial KL-6 (above 400U/ml) compared to the others (p=0.02). Moreover, in the prospective observation of 25 patients whose HCC was completely cured by radiofrequency ablation therapy, the cumulative incidence of distant recurrences was significantly greater in patients with high initial KL-6 compared to the others (p=0.005). These results suggest that serum KL-6 could be a novel tumor marker in the diagnosis and the prediction of prognosis of HCC that may have additive value to the existent markers.

    Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Publishing Authors By Initials

    m kurosakiM Kurosaki,n izumiN Izumi,y onukiY Onuki,y nishimuraY Nishimura,k uedaK Ueda,k tsuchiyaK Tsuchiya,h nakanishiH Nakanishi,t kitamuraT Kitamura,y asahinaY Asahina,m uchiharaM Uchihara,s miyakeS Miyake,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Hepatology research : the official journal of the

    VOLUME: 33

    Page Numbers: 250-7

    Journal Abbreviation:

    ISSN: 1386-6346

    DAY: 30

    MONTH: 09

    YEAR: 2005

    Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9711801

    Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients.

    AFFILIATION: Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 1-26-1 Kyonan-cho, Musashino-shi, Tokyo 180-8610, Japan.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Hepatol Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News